International Journal of Ophthalmic PathologyISSN: 2324-8599

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Three-year Outcomes of a Treat-and-Extend Regimen of Intravitreal Aflibercept for Wet ARMD at the Western Eye Hospital

Wet age-related macular degeneration wARMD is the leading cause of central visual loss in elderly patients in the developed countries. Overexpression of vascular endothelial grown factor (VEGF) is known to play a major role in the pathogenesis of choroidal neovascularization. Aflibercept is a fully human, recombinant fusion protein that inhibits VEGF. It has a higher tendency to combine with VEGF-A and it blocks other factors such as VEGF-B and placental growth.

Special Features

Full Text

View

Track Your Manuscript

Media Partners

GET THE APP